FDA reverses surprise rejection of Moderna's mRNA flu vaccine

The FDA has reversed its initial rejection of Moderna's mRNA-based flu vaccine. The decision was initially made by the Trump administration's vaccine chief, who overruled the FDA scientists. The vaccine, which uses the same mRNA technology as Moderna's COVID-19 shot, was rejected by the FDA, citing concerns about its effectiveness. However, after further review, the FDA has now approved the vaccine, stating that it is effective in preventing the flu. This reversal highlights the ongoing debate around the use of mRNA technology in vaccines, as well as the potential political interference in the regulatory process. The approval of Moderna's mRNA flu vaccine is seen as a significant step forward in the development of alternative vaccine technologies, which could potentially lead to the creation of more effective and adaptable vaccines in the future. The decision also underscores the importance of maintaining the independence and integrity of the FDA's scientific decision-making process.